Lord, Abbett & Co
VRDN icon

Lord, Abbett & Co’s Viridian Therapeutics VRDN Stock Holding History

Lord, Abbett & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-459,588
Closed -$8.81M – 586
2024
Q4 		$8.81M Buy
459,588
+67,630
+17% +$1.47M 0.03% 399
2024
Q3 		$8.92M Buy
+391,958
New +$6.41M 0.03% 413

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Lord, Abbett & Co's VRDN Position: Q1 2025 in Review

Lord, Abbett & Co sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 459,588 shares — an estimated $8.81M sold.

Lord, Abbett & Co first reported a position in VRDN in Q3 2024 and held it in 2 quarters. The position peaked at $8.92M in Q3 2024. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

  • Lord, Abbett & Co reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 459,588 Viridian Therapeutics shares in Q1 2025, an estimated $8.81M.
  • Lord, Abbett & Co first reported a position in Viridian Therapeutics in Q3 2024 and held it in 2 quarters.
  • Lord, Abbett & Co's Viridian Therapeutics position peaked at $8.92M in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Lord, Abbett & Co's 13F filing for Q1 2025, filed 13 May 2025.